Form 4: Acurx Pharmaceuticals Director Acquires Shares and Warrants in Direct Offering

Robert J. DeLuccia, a director at Acurx Pharmaceuticals, purchased shares and warrants in a registered direct offering and concurrent private placement.

Summary

• On January 6, 2025, Robert J. DeLuccia, a director at Acurx Pharmaceuticals, acquired 49,261 shares of common stock at a price of $1.015 per share.
• The acquisition was part of a registered direct offering by Acurx Pharmaceuticals.
• DeLuccia also acquired warrants for 49,261 shares of common stock at a price of $0 in a concurrent private placement.
• These warrants are exercisable from January 7, 2025, and expire on January 7, 2030, with an exercise price of $0.9.
• Following these transactions, DeLuccia directly owns 1,010,196 shares of common stock and indirectly owns 3,847 shares through his spouse.
• He also directly owns 49,261 warrants for common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's investment in the company, signaling confidence. However, it's important to consider the context of the direct offering, which may indicate a need for capital.

Positives

• A director's purchase of shares and warrants can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the director's investment suggests a positive outlook.

Industry Context

Direct offerings and private placements are common financing methods for pharmaceutical companies, especially those in the development stage. Director participation is often viewed favorably by investors.

Comparison to Industry Standards

• Comparable companies in the pharmaceutical sector, such as BioCryst Pharmaceuticals or Idera Pharmaceuticals, often utilize direct offerings to raise capital.
• Director participation in such offerings is a common practice, aligning management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the director's purchase positively.
• The capital raised through the direct offering can support the company's operations and development programs.

Key Dates